A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Ozempic gains expanded approval; Boxed Warning added to MS treatment label; Monotherapy approval granted to Spravato; Leqembi gains maintenance regimen; Enhertu gains new breast cancer indication.

Data from the off-treatment period between the Study 201 (Phase 2) core study and LTE showed that discontinuation of treatment is associated with reaccumulation of amyloid PET and plasma and CSF ...

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance ... 4 weeks 10mg/kg dosing regimen following ...

LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease ...

(MENAFN- JCN NewsWire) FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for ...

intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively ...

New Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase-III Clinical Trial ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...